Inhibiting MEK in MAPK pathway-activated myeloma

Leukemia. 2016 Apr;30(4):976-80. doi: 10.1038/leu.2015.208. Epub 2015 Jul 31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Cyclin D2 / genetics
  • Follow-Up Studies
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Integrin beta Chains / genetics
  • MAP Kinase Kinase 1 / antagonists & inhibitors*
  • MAP Kinase Signaling System / genetics*
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / pathology
  • Neoplasm Staging
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*
  • Receptors, CCR1 / genetics
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • CCND2 protein, human
  • CCR1 protein, human
  • Cyclin D2
  • Integrin beta Chains
  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • Receptors, CCR1
  • integrin beta7
  • trametinib
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human